Wen Chen

Wen Chen has served as a board member of Verseau since March 2017. He is the Senior Vice President of Tigermed Co. Ltd., a publicly-traded company located in China. Tigermed is a leading contract research organization in China, the Asia Pacific dedicated to providing professional clinical development services to the pharmaceutical and medical device industries. Wen represents Yonghua Capital, leading private equity and venture capital investment firm from China that has invested in Verseau Therapeutics.

Wen received a bachelor’s degree in biochemistry from Purdue University, West Lafayette, IN and a master’s degree in immunology and oncology and business administration from Washington University in St. Louis and Durham University, respectively.

He then worked at Amgen research before returning to work in the China biotechnology industry in 2000.